全文获取类型
收费全文 | 2059篇 |
免费 | 113篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 17篇 |
妇产科学 | 85篇 |
基础医学 | 310篇 |
口腔科学 | 15篇 |
临床医学 | 195篇 |
内科学 | 326篇 |
皮肤病学 | 22篇 |
神经病学 | 220篇 |
特种医学 | 103篇 |
外科学 | 295篇 |
综合类 | 9篇 |
一般理论 | 2篇 |
预防医学 | 77篇 |
眼科学 | 138篇 |
药学 | 114篇 |
中国医学 | 8篇 |
肿瘤学 | 218篇 |
出版年
2023年 | 18篇 |
2022年 | 17篇 |
2021年 | 33篇 |
2020年 | 34篇 |
2019年 | 38篇 |
2018年 | 43篇 |
2017年 | 25篇 |
2016年 | 53篇 |
2015年 | 51篇 |
2014年 | 81篇 |
2013年 | 101篇 |
2012年 | 128篇 |
2011年 | 151篇 |
2010年 | 95篇 |
2009年 | 99篇 |
2008年 | 152篇 |
2007年 | 143篇 |
2006年 | 136篇 |
2005年 | 158篇 |
2004年 | 134篇 |
2003年 | 146篇 |
2002年 | 132篇 |
2001年 | 30篇 |
2000年 | 17篇 |
1999年 | 20篇 |
1998年 | 17篇 |
1997年 | 21篇 |
1996年 | 11篇 |
1995年 | 12篇 |
1994年 | 11篇 |
1993年 | 6篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 4篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1969年 | 2篇 |
1966年 | 1篇 |
1926年 | 1篇 |
排序方式: 共有2178条查询结果,搜索用时 15 毫秒
1.
Achim Rosemann Adam Balen Brigitte Nerlich Christine Hauskeller Margaret Sleeboom‐Faulkner Sarah Hartley Xinqing Zhang Nick Lee 《The Hastings Center report》2019,49(3):30-42
A central problem for the international governance of heritable germline gene editing is that there are important differences in attitudes and values as well as ethical and health care considerations around the world. These differences are reflected in a complicated and diverse regulatory landscape. Several publications have discussed whether reproductive uses would be legally permissible in individual countries and whether clinical applications could emerge in the context of regulatory gaps and gray areas. Systematic comparative studies that explore issues related to the governance of this technology from different national and international perspectives are needed to address the lack of knowledge in this area. In this research report, we contribute to filling this gap by presenting views of stakeholders in the United Kingdom on challenges to the governance of heritable genome editing. We present findings from a multistakeholder study conducted in the United Kingdom between October 2016 and January 2018 and funded by the Wellcome Trust. This research included interviews, literature analysis, and a workshop. We involved leading U.K. scientists, in vitro fertilization clinicians, and representatives from regulatory bodies, patient organizations, and other civil societal organizations, as well as fertility companies. Part one of this article explores stakeholder perceptions of possible global developments in heritable genome editing and associated risks and governance challenges. Part two presents a range of policy options that were generated during the workshop in relation to the challenges discussed in part one. 相似文献
2.
Helmer Philipp Schlesinger Tobias Hottenrott Sebastian Papsdorf Michael Wöckel Achim Diessner Joachim Stumpner Jan Sitter Magdalena Skazel Tobias Wurmb Thomas Härtel Christoph Hofer Stefan Alkatout Ibrahim Girard Thierry Meybohm Patrick Kranke Peter 《Der Anaesthesist》2022,71(3):171-180
Die Anaesthesiologie - Die Implementierung eines Patient Blood Management (PBM) wird zunehmender Standard in der operativen Medizin. Seit einiger Zeit gilt das Interesse auch den vulnerablen... 相似文献
3.
4.
5.
6.
7.
Markus Mandler Elvira Valera Edward Rockenstein Harald Weninger Christina Patrick Anthony Adame Radmila Santic Stefanie Meindl Benjamin Vigl Oskar Smrzka Achim Schneeberger Frank Mattner Eliezer Masliah 《Acta neuropathologica》2014,127(6):861-879
Immunotherapeutic approaches are currently in the spotlight for their potential as disease-modifying treatments for neurodegenerative disorders. The discovery that α-synuclein (α-syn) can transmit from cell to cell in a prion-like fashion suggests that immunization might be a viable option for the treatment of synucleinopathies. This possibility has been bolstered by the development of next-generation active vaccination technology with short peptides-AFFITOPEs® (AFF)- that do not elicit an α-syn-specific T cell response. This approach allows for the production of long term, sustained, more specific, non-cross reacting antibodies suitable for the treatment of synucleinopathies, such as Parkinson’s disease (PD). In this context, we screened a large library of peptides that mimic the C-terminus region of α-syn and discovered a novel set of AFF that identified α-syn oligomers. Next, the peptide that elicited the most specific response against α-syn (AFF 1) was selected for immunizing two different transgenic (tg) mouse models of PD and Dementia with Lewy bodies, the PDGF- and the mThy1-α-syn tg mice. Vaccination with AFF 1 resulted in high antibody titers in CSF and plasma, which crossed into the CNS and recognized α-syn aggregates. Active vaccination with AFF 1 resulted in decreased accumulation of α-syn oligomers in axons and synapses, accompanied by reduced degeneration of TH fibers in the caudo-putamen nucleus and by improvements in motor and memory deficits in both in vivo models. Clearance of α-syn involved activation of microglia and increased anti-inflammatory cytokine expression, further supporting the efficacy of this novel active vaccination approach for synucleinopathies. 相似文献
8.
Corinna Trebst Sven Jarius Achim Berthele Friedemann Paul Sven Schippling Brigitte Wildemann Nadja Borisow Ingo Kleiter Orhan Aktas Tania Kümpfel 《Journal of neurology》2014,261(1):1-16
Neuromyelitis optica (NMO, Devic’s syndrome), long considered a clinical variant of multiple sclerosis, is now regarded as a distinct disease entity. Major progress has been made in the diagnosis and treatment of NMO since aquaporin-4 antibodies (AQP4-Ab; also termed NMO-IgG) were first described in 2004. In this review, the Neuromyelitis Optica Study Group (NEMOS) summarizes recently obtained knowledge on NMO and highlights new developments in its diagnosis and treatment, based on current guidelines, the published literature and expert discussion at regular NEMOS meetings. Testing of AQP4-Ab is essential and is the most important test in the diagnostic work-up of suspected NMO, and helps to distinguish NMO from other autoimmune diseases. Furthermore, AQP4-Ab testing has expanded our knowledge of the clinical presentation of NMO spectrum disorders (NMOSD). In addition, imaging techniques, particularly magnetic resonance imaging of the brain and spinal cord, are obligatory in the diagnostic workup. It is important to note that brain lesions in NMO and NMOSD are not uncommon, do not rule out the diagnosis, and show characteristic patterns. Other imaging modalities such as optical coherence tomography are proposed as useful tools in the assessment of retinal damage. Therapy of NMO should be initiated early. Azathioprine and rituximab are suggested as first-line treatments, the latter being increasingly regarded as an established therapy with long-term efficacy and an acceptable safety profile in NMO patients. Other immunosuppressive drugs, such as methotrexate, mycophenolate mofetil and mitoxantrone, are recommended as second-line treatments. Promising new therapies are emerging in the form of anti-IL6 receptor, anti-complement or anti-AQP4-Ab biologicals. 相似文献
9.
10.